Clinical trialNCT06975293RecruitingPhase 1/PHASE2Interventional

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

SponsorSTORM Therapeutics LTDEnrollment107Dedifferentiated LiposarcomaLeiomyosarcomaSarcomaSolid Tumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sandra Tong, MD
Storm Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, San Francisco
San Francisco, California, United States
Varun Monga, MBBS
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Andrew J Wagner, MD, PhD
Recruiting
Northwell Health Cancer Institute
Lake Success, New York, United States
Anthony Philip, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Elise Nassif, MD
Not, yet, recruiting
Next Houston
Houston, Texas, United States
Jennifer Segar, MD
Recruiting
Next Dallas
Irving, Texas, United States
Faran Polani, MD
Recruiting
Next Oncology
San Antonio, Texas, United States
Ildefonso I Rodriguez Rivera, MD
Recruiting
the Start Center
San Antonio, Texas, United States
Kyriakos Papadopoulos, MD
Recruiting
Next Oncology
Fairfax, Virginia, United States
M. Adham Salkeni, MD, FRCPC
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

STC-15 monotherapy

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 May 2025
Primary completion: 29 Dec 2027
Completion: 29 Jun 2028
Last update posted: 20 Jul 2026
Registered enrollment: 107
Registry id: NCT06975293

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.